Edinburgh MoonWalk 2025 to be the last in the city after 19 years
Scotland's MoonWalk has raised £22 million since the event was first staged in 2006.
The event usually starts and finishes at Holyrood Park with walkers taking to the route in decorated bras and bright lights, however, a new route is expected due to the park's road being closed.
This year's event is set to take place on September 6.
READ MORE: 'Show some respect': Scots hit out at Danish influencer for 'damaging' protected land
Funds awarded by Walk the Walk make a huge difference to people across Scotland living with cancer. Recent grants have been made to the Beatson Cancer Charity, Ayrshire Cancer Support and Make 2nds Count.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
26 minutes ago
- Reuters
Canada approves Ozempic to cut risk of kidney failure, heart-related deaths
Aug 19 (Reuters) - Canada has approved Novo Nordisk's ( opens new tab diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of kidney failure and heart-related deaths in type-2 diabetes patients, the company said Tuesday. Ozempic, chemically known as semaglutide, is now the first approved treatment in Canada for type 2 diabetes and to slow related kidney disease, according to the Danish drugmaker. Novo said Tuesday's approval from Health Canada was backed by late-stage trial data that showed a 1 milligram dose of Ozempic cut the risk of kidney-related death and major cardiac events by 24%. Novo and U.S. rival Eli Lilly (LLY.N), opens new tab have been racing for more than two years to prove their competing GLP-1 drugs, already shown to be powerful weight-loss agents and diabetes treatments, can also be used to tackle other major diseases and potentially expand insurance coverage. Ozempic won U.S. approval earlier this year to reduce kidney disease progression and death. Wegovy, Novo's obesity drug that shares Ozempic's active ingredient, was last week cleared in the U.S. to treat metabolic dysfunction–associated steatohepatitis, a serious progressive liver disease. The U.S. Food and Drug Administration last December approved Lilly's obesity drug, Zepbound, for obstructive sleep apnea. Novo Nordisk estimates that around 40% of people with type 2 diabetes have chronic kidney disease, which affects about 4 million people in Canada and 37 million in the U.S.
Daily Record
2 hours ago
- Daily Record
Ayrshire Cancer Support fundraising campaign returns this September
This September walk, run, cycle, swim or however you like to move, and turn your miles into support for people affected by cancer across Ayrshire Ayrshire Cancer Support encouraging people to take part in Ayrshire to Beatson challenge to support all those affected by cancer within the local community. The Ayrshire Cancer Support challenge is simple: pick a distance that reflects one of the real patient journeys to The Beatson in Glasgow, from 62 to 120 miles, and complete it throughout the month of September. Every step you take will help raise awareness and funds for vital services like the Ayrshire Cancer Support volunteer transport service to and from treatment. Throughout September, rally your colleagues to run, walk, cycle or swim towards the chosen target. Every mile counts and every step makes a difference for those affected by cancer within the Ayrshire community. Karen McIntyre, Chief Executive at Ayrshire Cancer Support said: "Ayrshire to Beatson is a fantastic campaign that allows supporters to choose their event, their distance, and when they want to complete their challenge. You can walk, run, cycle or swim to get healthy, and crucially you'll be supporting local people and their loved ones who are coping with cancer." She added: 'Whether you're recently diagnosed, undergoing treatment, caring for a loved one or recently bereaved, Ayrshire Cancer Support is here for you. Our comprehensive services are professional and compassionate, from volunteer drivers who take people to appointments, to our counselling support and peer groups. Please help us deliver this care for local people by signing up and getting involved." To sign up for Ayrshire to Beatson challenge, please visit here.
Reuters
2 hours ago
- Reuters
Canada approves Ozempic to reduce risk of diabetic kidney disease progression
Aug 19 (Reuters) - Canada's health regulator has approved Novo Nordisk's ( opens new tab diabetes drug, Ozempic, for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease, the Danish drugmaker said on Tuesday.
